{"id":"NCT04855760","sponsor":"Relmada Therapeutics, Inc.","briefTitle":"Safety of REL-1017 for Major Depressive Disorder","officialTitle":"A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-01","primaryCompletion":"2023-07-27","completion":"2023-07-27","firstPosted":"2021-04-22","resultsPosted":"2024-08-09","lastUpdate":"2025-02-11"},"enrollment":627,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"REL-1017","otherNames":["Esmethadone HCl"]}],"arms":[{"label":"REL-1017","type":"EXPERIMENTAL"}],"summary":"This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder. Adjunctive study participants continued to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.","primaryOutcome":{"measure":"Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"52 weeks","effectByArm":[{"arm":"REL-1017","deltaMin":350,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":["39999772"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":624},"commonTop":["Headache","COVID-19","Upper respiratory tract infections"]}}